Brind.

Jefferies Financial Group provided price targets for Fate Therapeutics stock on July 9, 2026.

2 reports, 1 independent Updated Aug 14

Gone quiet

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Jefferies Financial Group provided price targets for Fate Therapeutics stock on July 9, 2026.

Who's involved

What this event is mainly about

Fate Therapeutics Jefferies Financial Group

Keep exploring

The entities involved

Fate Therapeutics
a clinical-stage biopharmaceutical company in San Diego, United States
- Fate Therapeutics, based in San Diego, is seeking support for an accelerated regulatory pathway from the FDA.Fri 12:48
- Fate Therapeutics announced from its operational base that it is targeting the U.S. market for clinical trials.Fri 12:48
Jefferies Financial Group
American financial services company
- Apple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Mon 17:22
- Jefferies reaffirmed Amazon's stock buy rating on June 18, 2026.Mon 12:11

Related events

Coverage

Newest first; wire copies grouped

Jul 9dailypolitical.com

1 more outlet ran the same wire story

Aug 14themarketsdaily.com